Kamada Ltd. (NASDAQ:KMDA - Get Free Report) declared a dividend on Wednesday, March 5th, NASDAQ Dividends reports. Shareholders of record on Monday, March 17th will be given a dividend of 0.20 per share by the biotechnology company on Monday, April 7th. The ex-dividend date of this dividend is Monday, March 17th.
Kamada Trading Down 1.3 %
Shares of KMDA traded down $0.09 on Tuesday, reaching $6.99. The company's stock had a trading volume of 89,953 shares, compared to its average volume of 258,793. Kamada has a twelve month low of $4.74 and a twelve month high of $9.15. The stock has a market capitalization of $401.79 million, a PE ratio of 24.96, a PEG ratio of 0.97 and a beta of 0.97. The firm has a fifty day moving average of $7.13 and a 200-day moving average of $6.17.
Analyst Upgrades and Downgrades
Separately, HC Wainwright reissued a "buy" rating and issued a $11.00 price objective on shares of Kamada in a research note on Thursday, March 6th.
Check Out Our Latest Stock Report on KMDA
About Kamada
(
Get Free Report)
Kamada Ltd. manufactures and sells plasma-derived protein therapeutics. Its commercial products include KAMRAB/KEDRAB for treating prophylaxis of rabies; CYTOGAM for Prophylaxis of Cytomegalovirus disease in kidney, lung, liver, pancreas, heart, and heart/lung transplants; VARIZIG for post exposure prophylaxis of varicella; WINRHO SDF for immune thrombocytopenic purpura and suppression of rhesus isoimmunization; HEPAGAM B for prevention of hepatitis B recurrence liver transplants and post-exposure prophylaxis; GLASSIA for intravenous AATD; KAMRHO (D) IM for prophylaxis of hemolytic disease of newborns; KAMRHO (D) IV for immune thermobocytopunic purpura; and Echis coloratus and Vipera palaestinae Antiserum for the treatment of snake bite.
Featured Stories
Before you consider Kamada, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Kamada wasn't on the list.
While Kamada currently has a Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Looking to profit from the electric vehicle mega-trend? Enter your email address and we'll send you our list of which EV stocks show the most long-term potential.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
